Loading...
XPAR
VETO
Market cap947mUSD
Jul 09, Last price  
71.30EUR
1D
0.28%
1Q
-11.10%
Jan 2017
56.60%
IPO
210.00%
Name

Vétoquinol

Chart & Performance

D1W1MN
XPAR:VETO chart
P/E
14.46
P/S
1.58
EPS
4.93
Div Yield, %
1.25%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
4.22%
Revenues
526m
-2.50%
211,591,000233,364,000234,395,000257,057,000282,041,000284,137,000298,293,000299,727,000315,298,000342,612,000350,354,000352,173,000367,941,000395,990,000427,467,000521,272,000539,779,000529,271,000539,196,000525,700,000
Net income
57m
-2.36%
15,824,00018,642,00018,564,00018,207,00022,255,00022,695,00022,569,00023,580,00025,766,00024,156,00027,827,00034,831,00036,259,00028,589,00019,221,00062,861,00047,995,00055,560,00058,685,00057,300,000
CFO
72m
-16.02%
23,356,00037,215,00021,903,00040,046,00034,360,00029,992,00034,209,00028,106,00041,298,00038,897,00043,205,00041,225,00037,884,00052,024,00092,012,00089,715,00062,855,00089,391,00085,826,00072,076,000
Dividend
Jun 04, 20250.89 EUR/sh
Earnings
Sep 09, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vetoquinol S.A. is a pharmaceutical company dedicated to animal health, responsible for researching, formulating, and distributing veterinary medicines and other health-related products throughout Europe, the Americas, and the Asia Pacific. The firm offers a comprehensive range of solutions for various therapeutic areas, including pain and mobility management, inflammatory conditions, dermatology, hygiene, parasite control, udder health, infectious diseases, reproductive care, behavioral issues, internal medicine, and cardiovascular-renal disorders. These products are developed for a diverse clientele of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside domestic dogs. Founded in 1933, Vetoquinol S.A. maintains its headquarters in Lure, France, and operates as a subsidiary of Soparfin SCA.
IPO date
Nov 16, 2006
Employees
2,455
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT